ICON plc (ICLR) Stock Price & How to Invest

ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. As of March 2026 it had roughly 40,350 employees across about 97 locations in 55 countries, and it manages studies spanning compound selection through Phase I to Phase IV trials. Revenue is booked against a large backlog, so bookings and book-to-bill ratios are watched as closely as reported sales.

The investment picture in 2026 is a story of scale meeting a demand air pocket. First-quarter 2026 revenue was roughly $2.03 billion, up about 0.9% reported but down 1.9% at constant currency, while adjusted EPS fell to about $2.50 from $3.27 a year earlier as adjusted EBITDA margin dropped sharply. At the same time net bookings were about $2.9 billion with a book-to-bill near 1.42 and backlog around $22.7 billion, signaling that future work is being won even as current results soften. The stock trades at a low-teens trailing earnings multiple, reflecting caution about margins, a disclosed internal accounting investigation, and the pace of pharma spending recovery.

ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. Margin pressure has been acute, with adjusted EBITDA margin falling to about 15.6% in Q1 2026 from the high-teens to roughly 20% range previously. Concentration among a handful of Top 10 pharma clients means mergers or pipeline cuts at a few customers can materially affect revenue. The company disclosed an internal accounting investigation and potential restatements, which prompted at least one analyst downgrade and adds uncertainty until resolved. Full-year 2026 revenue guidance of roughly $7.85 billion to $8.15 billion sits below 2025 levels, reflecting both a divestiture and organic softness.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see ICON plc's investor relations page or your broker.

• Market cap: ~$8.9B
• Revenue (TTM): ~$8.1B
• Q1 2026 revenue: ~$2.03B
• Q1 2026 adjusted EPS: ~$2.50
• P/E (trailing): ~14-15x
• 2026 revenue guidance: ~$7.85B-$8.15B

ICON reaffirmed full-year 2026 guidance of roughly $7.85 billion to $8.15 billion in revenue and about $10.00 to $11.00 in adjusted diluted EPS. The low-teens trailing multiple reflects softer near-term margins and demand, while backlog of around $22.7 billion underpins forward visibility. Figures are approximate and drawn from company filings and market data.

There are three common ways to get ICLR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ICLR sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ICLR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

ICON is a scaled, backlog-rich CRO trading at a compressed multiple because near-term growth and margins have softened, so the story hinges on whether pharma and biotech demand reaccelerates.

Whether ICLR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ICLR a buy?, and where the stock could go from here in the ICLR stock forecast.

For income investors, whether ICLR pays a dividend and how the payout looks is covered in does ICLR pay a dividend?